
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="../style.css">
    <title>Document</title>
</head>
<body>

<span class="table_title">False Negatives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>8</th>
      <td></td>
      <td>females</td>
      <td>The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.</td>
    </tr>
    <tr>
      <th>5</th>
      <td></td>
      <td>women</td>
      <td>There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.</td>
    </tr>
    <tr>
      <th>0</th>
      <td></td>
      <td>male<br>female</td>
      <td>Regarding CAM nonusers, the majority were in the age group of 20–60 years with the male/female ratio of 73/27 percent.</td>
    </tr>
    <tr>
      <th>7</th>
      <td></td>
      <td>man</td>
      <td>Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic® Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.</td>
    </tr>
    <tr>
      <th>4</th>
      <td></td>
      <td>women</td>
      <td>We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.</td>
    </tr>
    <tr>
      <th>2</th>
      <td></td>
      <td>women<br>female</td>
      <td>Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone–related cancers; 4) women with uncontrolled hypertension (160/100 mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1 yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk; 12) women who were administered female hormone formulations within 6 mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10 h) within 3 mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1 mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.</td>
    </tr>
    <tr>
      <th>6</th>
      <td></td>
      <td>Female</td>
      <td>Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.</td>
    </tr>
  </tbody>
</table>
<span class="table_title">False Positives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>10</th>
      <td>male</td>
      <td></td>
      <td>daily for two weeks at morning and a single captopril dose (4.5 mg/200 g BW; p.o.)</td>
    </tr>
    <tr>
      <th>13</th>
      <td>humans</td>
      <td></td>
      <td>Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].</td>
    </tr>
    <tr>
      <th>12</th>
      <td>MK</td>
      <td></td>
      <td>Author contributions: MK drafted the initial and final versions of the manuscript.</td>
    </tr>
    <tr>
      <th>2</th>
      <td>pregnant women<br>breastfeeding women</td>
      <td></td>
      <td>Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.</td>
    </tr>
    <tr>
      <th>4</th>
      <td>male</td>
      <td></td>
      <td>The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.</td>
    </tr>
    <tr>
      <th>7</th>
      <td>women</td>
      <td></td>
      <td>Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].</td>
    </tr>
    <tr>
      <th>0</th>
      <td>rat</td>
      <td></td>
      <td>However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).</td>
    </tr>
    <tr>
      <th>8</th>
      <td>she</td>
      <td></td>
      <td>At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.</td>
    </tr>
    <tr>
      <th>1</th>
      <td>rats</td>
      <td></td>
      <td>In the present study, the selectivity was examined using independent plasma samples from six different rats.</td>
    </tr>
    <tr>
      <th>5</th>
      <td>subject with pruritus and hot flash<br>subject with headache</td>
      <td></td>
      <td>In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.</td>
    </tr>
    <tr>
      <th>11</th>
      <td>rats</td>
      <td></td>
      <td>And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.</td>
    </tr>
    <tr>
      <th>9</th>
      <td>rats</td>
      <td></td>
      <td>As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].</td>
    </tr>
  </tbody>
</table>

</body>
</html>
